Ph 1 Trial of E6201 + Dabrafenib initiated in Patients with CNS Metastases from BRAF V600 Mutated Metastatic Melanoma
“E6201 is a potent MEK1 inhibitor. Exceptional responses were seen with E6201 monotherapy in patients with melanoma brain metastases in our prior Phase 1 studies. By utilizing a targeted drug against BRAF- or MEK-mutated melanoma CNS metastases with excellent brain penetration and retention, we hope to provide a more effective therapeutic in combination with dabrafenib than achieved with the currently available targeted agents and immunotherapies,” said Dr. Linda Paradiso, Chief Development Officer for Spirita Oncology. “We are fully committed to deliver breakthrough therapies using innovative approaches for patients with devastating metastatic brain melanoma.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
